Literature DB >> 32304419

Nebulized Bacteriophages for Prophylaxis of Experimental Ventilator-Associated Pneumonia Due to Methicillin-Resistant Staphylococcus aureus.

Josef Prazak1, Luca Valente1,2, Manuela Iten1, Denis Grandgirard2, Stephen L Leib2, Stephan M Jakob1, Matthias Haenggi1, Yok-Ai Que1, David R Cameron1.   

Abstract

OBJECTIVES: There is a need for alternative strategies to combat and prevent antibiotic-resistant bacterial infections. Here, we assessed the potential for bacteriophage prophylaxis in the context of experimental ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus in rats.
DESIGN: Nebulized phages (aerophages) were delivered to the lungs of rats using a modified vibrating mesh aerosol drug delivery system. Animals were intubated and ventilated for 4 hours, at which point they were infected with methicillin-resistant S. aureus strain AW7 via the endotracheal tube, extubated, and then monitored for 96 hours.
SETTING: Ventilator-associated pneumonia.
SUBJECTS: Male Wistar rats.
INTERVENTIONS: A single application of aerophages prior to ventilation at one of two concentrations (~1010 plaque forming units/mL or ~1011 plaque forming units/mL).
MEASUREMENTS AND MAIN RESULTS: 1) Animal survival at 96 hours, 2) enumeration of bacteria and phages in the lungs and spleen, and 3) lung tissue histopathology. Animals that received aerophages prior to ventilation and methicillin-resistant S. aureus challenge showed a higher survival rate compared with untreated controls (60% for animals that received 3 × 10 plaque forming units; 70% for animals that received 3 × 10 plaque forming units; 0% for controls; p < 0.01 for each treatment versus untreated). Surviving animals that received aerophage prophylaxis had fewer methicillin-resistant S. aureus in the lungs compared with untreated control animals that succumbed to pneumonia (1.6 × 10 colony forming units/g vs 8.0 × 10; p < 0.01).
CONCLUSIONS: Prophylactically administered nebulized bacteriophages reduced lung bacterial burdens and improved survival of methicillin-resistant S. aureus infected rats, underscoring its potential in the context of ventilator-associated pneumonia.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32304419     DOI: 10.1097/CCM.0000000000004352

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  8 in total

Review 1.  Antimicrobial and Antibiofilm Coating of Dental Implants-Past and New Perspectives.

Authors:  Guilherme Melo Esteves; João Esteves; Marta Resende; Luzia Mendes; Andreia S Azevedo
Journal:  Antibiotics (Basel)       Date:  2022-02-11

Review 2.  Bacteriophages Could Be a Potential Game Changer in the Trajectory of Coronavirus Disease (COVID-19).

Authors:  Marcin W Wojewodzic
Journal:  Phage (New Rochelle)       Date:  2020-06-23

3.  Biomaterial-based delivery of antimicrobial therapies for the treatment of bacterial infections.

Authors:  Pranav P Kalelkar; Milan Riddick; Andrés J García
Journal:  Nat Rev Mater       Date:  2021-09-15       Impact factor: 66.308

Review 4.  Progress and Pitfalls of Bacteriophage Therapy in Critical Care: A Concise Definitive Review.

Authors:  Luca Valente; Josef Prazak; Yok-Ai Que; David R Cameron
Journal:  Crit Care Explor       Date:  2021-03-08

Review 5.  Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections.

Authors:  Xiang Wang; Zuozhou Xie; Jinhong Zhao; Zhenghua Zhu; Chen Yang; Yi Liu
Journal:  Front Cell Infect Microbiol       Date:  2021-12-06       Impact factor: 5.293

6.  Benefits of Aerosolized Phages for the Treatment of Pneumonia Due to Methicillin-Resistant Staphylococcus aureus: An Experimental Study in Rats.

Authors:  Josef Prazak; Luca G Valente; Manuela Iten; Lea Federer; Denis Grandgirard; Sara Soto; Gregory Resch; Stephen L Leib; Stephan M Jakob; Matthias Haenggi; David R Cameron; Yok-Ai Que
Journal:  J Infect Dis       Date:  2022-04-19       Impact factor: 7.759

7.  Bacteriophages Combined With Subtherapeutic Doses of Flucloxacillin Act Synergistically Against Staphylococcus aureus Experimental Infective Endocarditis.

Authors:  Jonathan Save; Yok-Ai Que; José M Entenza; Camille Kolenda; Frédéric Laurent; Grégory Resch
Journal:  J Am Heart Assoc       Date:  2022-01-19       Impact factor: 6.106

Review 8.  Exploring Virulence Factors and Alternative Therapies against Staphylococcus aureus Pneumonia.

Authors:  Jelle Vlaeminck; Dina Raafat; Kristin Surmann; Leen Timbermont; Nicole Normann; Bret Sellman; Willem J B van Wamel; Surbhi Malhotra-Kumar
Journal:  Toxins (Basel)       Date:  2020-11-18       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.